Spironolactone Tablet, Film Coated
Product Images NDC 0904-6927

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 0904-6927). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2c0f08d5 6d25 4525 87e0 1a340298d993 00

This packaging label is for spironolactone tablets, USP, 25 mg film-coated oral tablets by Major Pharmaceuticals. The label states the product is unit dose with 100 tablets per package, prescription only. It includes dosage form, strength, NDC 0904-6927-61, manufacturer details, storage conditions, and a barcode.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 01)

Chemical structure of spironolactone. The diagram depicts the molecular framework of spironolactone, showing its fused rings and functional groups including ketone, lactone, and thioacetate moieties.*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 02)

A Kaplan-Meier survival probability curve comparing spironolactone and placebo groups over a period of 42 months. The x-axis represents time in months, and the y-axis shows probability. The data include 822 subjects for spironolactone and 841 for placebo, highlighting a statistically significant difference (log-rank p < 0.001).*

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 03)

A forest plot showing hazard ratios (HR) and 95% confidence intervals (CI) for spironolactone versus placebo across various subgroups including age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The horizontal axis ranges from 0.2 to 1.4, with a vertical line at 1 indicating no difference between spironolactone and placebo. Sample sizes (N) and percentages for each subgroup are listed on the right.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.